10x Genomics, Inc.
TXG
Positions held
Your positionsTXG isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- 10x Genomics operates in the rapidly growing medical devices sector, focusing on genomic technologies that are essential for advancements in healthcare.
- The company's gross margin improved to 74.5% in the latest quarter, up from 70.4% in the previous quarter.
- The recommendation for 10x Genomics is a strong buy, with a score of 44.00, indicating positive investor sentiment.
- Despite its growth potential, 10x Genomics has faced significant revenue declines, with a year-over-year revenue growth of -12.7%.
- The company reported a net income loss of -255.099 million in 2023, reflecting ongoing financial challenges.
- Operating margin has been negative, with -15.2% in the latest quarter, indicating struggles with profitability.
Fundamentals
| Market cap | $10.07B | Enterprise value | $9.60B | Trailing P/E | — | Forward P/E | 1,007.96 |
| PEG | — | Price / book | 12.20 | Beta | 1.99 | Dividend yield | 0.00% |
| Revenue growth | -12.7% | Earnings growth | — | Gross margin | 70.1% | Operating margin | -15.2% |
| Profit margin | -12.2% | ROE | -9.4% | ROA | -5.0% | Debt / equity | 0.10 |
| Current ratio | 5.69 | Free cash flow | $179.66M | Analyst recommendation | buy | Mean target | $67.47 |
| 52w high | $102.81 | 52w low | $11.16 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $151M | $151M | $166M | $149M | $173M | — |
| Op margin | -15.2% | -11.3% | -11.8% | -21.6% | -6.1% | — |
| Net income | -$17.9M | -$13.5M | -$16.3M | -$27.5M | $34.5M | — |
| Gross margin | 74.5% | 70.4% | 68.1% | 67.3% | 72.3% | — |
| Gross profit | $112M | $106M | $113M | $100M | $125M | — |
| Operating income | -$23.0M | -$17.0M | -$19.5M | -$32.2M | -$10.6M | — |
- Revenue +0% vs prior quarter ($151M vs $151M).
- Gross margin 74.5% (was 70.4% prior quarter).
- Operating margin compressed to -15.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $643M | $611M | $619M | $516M | — |
| Op margin | -17.2% | -31.9% | -33.0% | -32.5% | — |
| Net income | -$43.5M | -$183M | -$255M | -$166M | — |
| Gross margin | 69.1% | 67.9% | 66.2% | 76.7% | — |
| Gross profit | $444M | $414M | $409M | $396M | — |
| Operating income | -$111M | -$195M | -$204M | -$168M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Is 10x Genomics (TXG) Using Its Fred Hutch Oncology Alliance To Redefine Its Clinical Moat?
2026-10-08 · 10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
2026-10-07 · 10x Genomics Enters Research Collaboration With Fred Hutchinson Cancer Center
2026-10-07 · Dow Jones Futures Fall, Yields Jump After S&P 500 Hits High; Astera, GE Vernova, Arista Lead Buys
2026-10-06 · NeoGenomics Sinks 12% on CEO Succession Plan Despite Revenue Beat
2026-10-06 · Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
2026-10-05 · 10x Genomics (TXG) Starts Atera Shipments And Sentira, Is The Upside Already Priced In?
2026-10-05 · Cathie Wood’s ARKG Is Crushing Her Other ETFs: 2 Biotech Bets Have Surged Nearly 6X This Year
2026-09-30 · 10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises
2026-09-29 · 10x Genomics Begins Commercial Shipments of Atera
Price (daily)
Full chart · RSI · MACD · patterns